AU2004220205B2 - Antitumor effect potentiator and antitumor agent - Google Patents

Antitumor effect potentiator and antitumor agent Download PDF

Info

Publication number
AU2004220205B2
AU2004220205B2 AU2004220205A AU2004220205A AU2004220205B2 AU 2004220205 B2 AU2004220205 B2 AU 2004220205B2 AU 2004220205 A AU2004220205 A AU 2004220205A AU 2004220205 A AU2004220205 A AU 2004220205A AU 2004220205 B2 AU2004220205 B2 AU 2004220205B2
Authority
AU
Australia
Prior art keywords
antitumor
tegafur
amount
enhancing
gimeracil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004220205A
Other languages
English (en)
Other versions
AU2004220205A1 (en
Inventor
Koyo Shudo
Junji Uchida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of AU2004220205A1 publication Critical patent/AU2004220205A1/en
Application granted granted Critical
Publication of AU2004220205B2 publication Critical patent/AU2004220205B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2004220205A 2003-03-14 2004-03-11 Antitumor effect potentiator and antitumor agent Ceased AU2004220205B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003-070097 2003-03-14
JP2003070097 2003-03-14
PCT/JP2004/003189 WO2004081012A1 (ja) 2003-03-14 2004-03-11 抗腫瘍効果増強剤及び抗腫瘍剤

Publications (2)

Publication Number Publication Date
AU2004220205A1 AU2004220205A1 (en) 2004-09-23
AU2004220205B2 true AU2004220205B2 (en) 2010-06-17

Family

ID=32984641

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004220205A Ceased AU2004220205B2 (en) 2003-03-14 2004-03-11 Antitumor effect potentiator and antitumor agent

Country Status (21)

Country Link
US (2) US9611227B2 (enExample)
EP (1) EP1604991B1 (enExample)
JP (1) JP4610481B2 (enExample)
KR (1) KR100812693B1 (enExample)
CN (2) CN101357134A (enExample)
AT (1) ATE408408T1 (enExample)
AU (1) AU2004220205B2 (enExample)
BR (1) BRPI0408372A (enExample)
CA (1) CA2518195C (enExample)
CY (1) CY1108395T1 (enExample)
DE (1) DE602004016636D1 (enExample)
DK (1) DK1604991T3 (enExample)
ES (1) ES2312978T3 (enExample)
MX (1) MXPA05009781A (enExample)
NZ (1) NZ542150A (enExample)
PL (1) PL1604991T3 (enExample)
PT (1) PT1604991E (enExample)
RU (1) RU2334517C2 (enExample)
SI (1) SI1604991T1 (enExample)
TW (1) TW200503720A (enExample)
WO (1) WO2004081012A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2603809C (en) * 2005-04-01 2011-12-06 Taiho Pharmaceutical Co., Ltd. Radiotherapy enhancer
CA2603810C (en) * 2005-04-01 2012-06-26 Taiho Pharmaceutical Co., Ltd. Potentiator for radiation therapy comprising pyridine derivative as active ingredient
JPWO2007043531A1 (ja) * 2005-10-07 2009-04-16 セレスター・レキシコ・サイエンシズ株式会社 抗腫瘍剤及び放射線併用療法感受性診断用遺伝子マーカー並びにその利用
WO2009139085A1 (ja) * 2008-05-12 2009-11-19 静岡県 抗腫瘍剤、キット及び癌治療方法
JP5553522B2 (ja) * 2009-03-31 2014-07-16 大鵬薬品工業株式会社 経口投与用医薬組成物
EP2422785B1 (en) * 2009-04-22 2019-11-06 Taiho Pharmaceutical Co., Ltd. Method for predicting therapeutic effect of chemotherapy on renal cell cancer
CN102309491B (zh) * 2010-07-02 2015-06-10 天津金耀集团有限公司 一种替加氟、吉美斯特复方注射液
MX353289B (es) * 2011-05-25 2018-01-05 Taiho Pharmaceutical Co Ltd Tableta revestida en seco que contiene tegafur, gimeracil y oteracil potasico.
US9694001B2 (en) * 2013-09-30 2017-07-04 Taiho Pharmaceutical Co., Ltd. Combination therapy using azabicyclo compound for cancer
CN106692173A (zh) * 2015-11-18 2017-05-24 北京诺普德医药科技有限公司 一种抗肿瘤复方组合物及其应用
CN106581001B (zh) * 2016-11-03 2018-12-21 江苏恒瑞医药股份有限公司 一种替吉奥组合物的制备方法
KR102258514B1 (ko) 2019-09-23 2021-05-31 연세대학교 산학협력단 신규한 다층형 좌약 제제

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004028A1 (en) * 1990-09-07 1992-03-19 Taiho Pharmaceutical Company, Limited Antineoplastic effect potentiator and antineoplastic agent
EP0543015A1 (en) * 1991-05-27 1993-05-26 Taiho Pharmaceutical Co., Ltd. Composition, method and kit for potentiating antitumor activity and for curing tumor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0443028B1 (en) 1989-01-05 1993-09-29 Otsuka Pharmaceutical Co., Ltd. Non-injection carcinostatic agent for suppressing occurrence of inflammation due to 5-fluorouracil and method for curing cancer
CH683262A5 (it) * 1992-01-22 1994-02-15 Applied Pharma Res Procedimento per la separazione dei diastereomeri del sale di calcio dell'acido (6(R,S)-N-formiltetraidrofolico).
WO2001066102A2 (en) * 2000-03-08 2001-09-13 Bristol-Myers Squibb Company Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
BR0207443A (pt) 2001-03-06 2004-04-06 Bristol Myeres Squibb Company Método e forma de dosagem para o tratamento de tumores pela administração de tegafur, uracila, ácido folìnico, paclitaxel e carboplatina
EP1411120B1 (en) * 2001-07-05 2010-01-13 Taiho Pharmaceutical Company Limited Dna arrays for measuring sensitivity to anticancer agent

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004028A1 (en) * 1990-09-07 1992-03-19 Taiho Pharmaceutical Company, Limited Antineoplastic effect potentiator and antineoplastic agent
EP0500953A1 (en) * 1990-09-07 1992-09-02 Taiho Pharmaceutical Company Limited Antineoplastic effect potentiator and antineoplastic agent
EP0543015A1 (en) * 1991-05-27 1993-05-26 Taiho Pharmaceutical Co., Ltd. Composition, method and kit for potentiating antitumor activity and for curing tumor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Britto Rogelio A et al., Oncology, 1999, Vol 57, Suppl 1, pp2-8 *
Ikeda Kazumasa et al., Antibiotics & Chemotherapy, 2001, Vol 17, No 7, pp 1318-1331 *
Isla M D et al., European Journal of Cancer, January 1997, Vol 33, No 1, pp166-167 *
Martoni A et al., Anticancer Research, 1992, Vol 12, pp 607-612 *
Royce M et al., Drugs and Aging, 2000, Vol 17, No 3, pp 201-216 *

Also Published As

Publication number Publication date
JP4610481B2 (ja) 2011-01-12
NZ542150A (en) 2009-09-25
CN101357134A (zh) 2009-02-04
US20060116345A1 (en) 2006-06-01
TWI295173B (enExample) 2008-04-01
DK1604991T3 (da) 2009-01-05
EP1604991A4 (en) 2006-05-03
ES2312978T3 (es) 2009-03-01
CY1108395T1 (el) 2014-02-12
PL1604991T3 (pl) 2009-02-27
US20170157131A1 (en) 2017-06-08
CN1761665A (zh) 2006-04-19
JPWO2004081012A1 (ja) 2006-06-08
TW200503720A (en) 2005-02-01
EP1604991A1 (en) 2005-12-14
RU2005131839A (ru) 2006-02-10
MXPA05009781A (es) 2005-10-26
WO2004081012A1 (ja) 2004-09-23
PT1604991E (pt) 2008-10-27
EP1604991B1 (en) 2008-09-17
AU2004220205A1 (en) 2004-09-23
US9611227B2 (en) 2017-04-04
BRPI0408372A (pt) 2006-03-21
DE602004016636D1 (de) 2008-10-30
RU2334517C2 (ru) 2008-09-27
KR20050106119A (ko) 2005-11-08
ATE408408T1 (de) 2008-10-15
CA2518195A1 (en) 2004-09-23
KR100812693B1 (ko) 2008-03-13
CA2518195C (en) 2009-07-07
US9814724B2 (en) 2017-11-14
SI1604991T1 (sl) 2009-02-28

Similar Documents

Publication Publication Date Title
US9814724B2 (en) Antitumor effect potentiator and antitumor agent
JP3208437B2 (ja) 癌転移抑制剤
JP2557303B2 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
US5534513A (en) Antitumor potentiator and antitumor composition
JPWO1992004028A1 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
AU2005251588B2 (en) Antitumor effect fortifier, antitumor agent and method of therapy for cancer
RU2519199C2 (ru) Противоопухолевый агент, набор и способ лечения рака
JP2767176B2 (ja) 抗癌剤
HK1127546A (en) Antitumor effect potentiator and antitumor agent

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired